ArticleFrontiers in medicine2026
Clinical application of different administration methods of tranexamic acid in transforaminal lumbar interbody fusion surgery.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: The purpose of this research was to investigate the effectiveness and safety associated with various administration routes of tranexamic acid (TXA) in transforaminal lumbar interbody fusion (TLIF) procedures. Methods: A cohort of 60 patients who underwent standard TLIF procedures was enrolled and categorized into three groups based on distinct TXA administration strategies: Group A (received preoperative intravenous TXA injection), Group B (received preoperative intravenous TXA injection followed by postoperative oral TXA for 3 days), and Group C (received preoperative intravenous TXA injection followed by postoperative oral TXA for 5 days). Comparative analyses were conducted among the three groups concerning surgical blood loss, operation time, length of hospital stay, hemoglobin and hematocrit levels, coagulation and fibrinolytic markers, transfusion requirements and transfusion rates, incidence of complications, and lumbar spine functionality. Results: In comparison to Group A, Groups B and C exhibited reduced total blood loss, concealed blood loss, and postoperative drainage volumes, along with shorter hospital stays. Additionally, Groups B and C demonstrated higher hemoglobin and hematocrit levels, along with lower transfusion rates ( Conclusion: Administration protocol involving preoperative intravenous TXA injection followed by 3 days of postoperative oral TXA can effectively decrease total and concealed blood loss, reduce postoperative drainage, shorten hospital stays, elevate hemoglobin and hematocrit levels, and diminish transfusion rates in patients undergoing TLIF surgery. This combined regimen shows a safety profile comparable to preoperative intravenous TXA alone, with no increase in complications or adverse events. Extending oral TXA to 5 days does not provide additional benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.